文献速递认知障碍与痴呆

高精度血浆β-淀粉样蛋白42/40预测当前及未来脑淀粉样变

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.
PubMed 文献 · Neurology · 2019-08-01

研究采用免疫沉淀-液相色谱-质谱法检测158例大多认知正常者的血浆与脑脊液Aβ42/Aβ40,并与淀粉样PET或脑脊液p-tau181/Aβ42比对。血浆Aβ42/Aβ40与淀粉样PET状态高度一致(AUC 0.88),联合年龄和APOE ε4状态后AUC达0.94。基线淀粉样PET阴性但血浆Aβ42/Aβ40阳性(<0.1218)者转化为PET阳性的风险增加15倍。

要点

  • 血浆Aβ42/Aβ40可准确诊断脑淀粉样变,联合年龄和APOE ε4状态预测价值更高。
  • 基线淀粉样PET阴性但血浆Aβ42/Aβ40阳性者转化为PET阳性的风险增加15倍。
  • 血浆Aβ42/Aβ40可用于筛查认知正常人群的脑淀粉样变及预防试验入组。

核心结论

  • 血浆Aβ42/Aβ40联合年龄和APOE ε4状态能准确诊断脑淀粉样变,并可预测未来淀粉样PET转阳风险。

研究设计与样本

  • 研究纳入158例大多认知正常的个体,在淀粉样PET扫描前18个月内采集血浆和脑脊液样本。
  • 采用免疫沉淀联合液相色谱-质谱法检测血浆和脑脊液Aβ42/Aβ40。
  • 以淀粉样PET或脑脊液p-tau181/Aβ42作为参考标准评估诊断准确性。

主要发现

  • 血浆Aβ42/Aβ40与淀粉样PET状态高度对应,AUC为0.88(95%CI 0.82-0.93)。
  • 血浆Aβ42/Aβ40与脑脊液p-tau181/Aβ42高度对应,AUC为0.85(95%CI 0.79-0.92)。
  • 血浆Aβ42/Aβ40联合年龄和APOE ε4状态与淀粉样PET的对应AUC为0.94(95%CI 0.90-0.97)。
  • 基线淀粉样PET阴性且血浆Aβ42/Aβ40阳性(<0.1218)者转化为淀粉样PET阳性的风险是血浆Aβ42/Aβ40阴性者的15倍(p=0.01)。

关键数值与推荐

  • 血浆Aβ42/Aβ40诊断淀粉样PET状态的AUC为0.88(95%CI 0.82-0.93)。
  • 血浆Aβ42/Aβ40联合年龄和APOE ε4状态诊断淀粉样PET状态的AUC为0.94(95%CI 0.90-0.97)。
  • 血浆Aβ42/Aβ40阳性定义为<0.1218,该阈值下基线淀粉样PET阴性者转化为阳性的风险增加15倍(p=0.01)。

临床怎么用

  • 血浆Aβ42/Aβ40可用于筛查认知正常个体的脑淀粉样变,减少PET或腰穿需求。
  • 联合年龄和APOE ε4状态可提高预测准确性,辅助筛选预防试验入组人群。
  • 对淀粉样PET阴性但血浆Aβ42/Aβ40阳性者,应警惕未来淀粉样PET转阳风险。

局限性

  • 研究样本以认知正常者为主,结论外推至其他人群需谨慎。
  • 研究提供Class II证据,尚需更大规模及多中心验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We examined whether plasma β-amyloid (Aβ)42/Aβ40, as measured by a high-precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p-tau181/Aβ42 as reference standards. METHODS: Using an immunoprecipitation and liquid chromatography-mass spectrometry assay, we measured Aβ42/Aβ40 in plasma and CSF samples from 158 mostly cognitively normal individuals that were collected within 18 months of an amyloid PET scan. RESULTS: Plasma Aβ42/Aβ40 had a high correspondence with amyloid PET status (receiver operating characteristic area under the curve [AUC] 0.88, 95% confidence interval [CI] 0.82-0.93) and CSF p-tau181/Aβ42 (AUC 0.85, 95% CI 0.79-0.92). The combination of plasma Aβ42/Aβ40, age, and APOE ε4 status had a very high correspondence with amyloid PET (AUC 0.94, 95% CI 0.90-0.97). Individuals with a negative amyloid PET scan at baseline and a positive plasma Aβ42/Aβ40 (<0.1218) had a 15-fold greater risk of conversion to amyloid PET-positive compared to individuals with a negative plasma Aβ42/Aβ40 (p = 0.01). CONCLUSIONS: Plasma Aβ42/Aβ40, especially when combined with age and APOE ε4 status, accurately diagnoses brain amyloidosis and can be used to screen cognitively normal individuals for brain amyloidosis. Individuals with a negative amyloid PET scan and positive plasma Aβ42/Aβ40 are at increased risk for converting to amyloid PET-positive. Plasma Aβ42/Aβ40 could be used in prevention trials to screen for individuals likely to be amyloid PET-positive and at risk for Alzheimer disease dementia. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that plasma Aβ42/Aβ40 levels accurately determine amyloid PET status in cognitively normal research participants.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019. PMID: 31371569. doi:10.1212/WNL.0000000000008081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。